Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Healthcare Biotechnology
Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Liminal BioSciences Inc.
Bullboard Posts
User Avatar Image
(104)
•••
Comment by foofadoooon Dec 06, 2017 10:24am
221 Views
Post# 27100306

RE:Re: NR

RE:Re: NRI am thinking the second presentation may provide info is looking for......

Presentation Title: Computer Modeling Using Historical Data Demonstrates a Significant Reduction in Expected Extravascular Fibrinous Lesions Due to Congenital Plasminogen Deficiency While Receiving Intravenous Plasminogen (PLG) Replacement 
Presenter: Joseph M. Parker, M.D. 
Session Title: Disorders of Coagulation or Fibrinolysis: Poster II 
Date/Time: Sunday, December 10, 2017 from 6:00 p.m. to 8:00 p.m. EST 
Room: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

 


Read more at https://www.stockhouse.com/news/press-releases/2017/12/06/pivotal-data-for-prometic-s-intravenous-plasminogen-replacement-therapy-to-be#3lRV21bAcwBzoFXq.99

i wouldn’t want to be out Monday morning....Christmas may come early...  foof
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities